SELECT PUBLICATIONS
Baka S et al. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 2006;10(6):867-76. Abstract
Cassidy J et al. XELOX vs FOLFOX4: Efficacy results from XELOX-1/NO16966, a
randomized phase III trial in first-line metastatic colorectal cancer (MCRC). Proc ASCO Gastrointestinal Cancers Symposium 2007; Abstract 270.
Cassidy J et al. First efficacy and safety results from XELOX-1/NO16966, a randomized 2x2 factorial phase III trial of XELOX vs FOLFOX4 1 bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). ESMO Congress 2006a;Abstract LBA3.
Cassidy J et al. Randomized double blind (DB) placebo (Plcb) controlled phase III
study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Proc ASCO 2006b; Abstract 3507.
Cassidy J et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for
patients with metastatic colorectal cancer. J Clin Oncol 2004;22(11):2084-91. Abstract
Diaz-Rubio E et al. Capecitabine (Xeloda) in combination with oxaliplatin: A phase I,dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13(4):558-65. Abstract
Fan F et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24(16):2647-53. Abstract
Gibson TB et al. Randomized phase III trial results of panitumumab, a fully human
anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6(1):29-31. Abstract
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Saltz LB et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Proc ASCO Gastrointestinal Cancers Symposium 2007;Abstract 238.
Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncol 2006;7(4):288. No abstract available
Van Cutsem E et al. Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment. Semin Oncol 2005;32(1):43-51. Abstract
Wainberg Z, Hecht JR. Panitumumab in colon cancer: A review and summary of
ongoing trials. Expert Opin Biol Ther 2006;6(11):1229-35. Abstract
Wedge SR et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial
growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400. Abstract
Williams KJ et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007;6(2):599-606. Abstract
